Acoramidis for ATTR-CM: TTR Stabilizer to Reduce CV Death and Hospitalization

　　1.Indication Boundary

　　Acoramidis(Attruby)was FDA-approved in November 2024 for adults with wild-type or hereditary transthyretin amyloidosis cardiomyopathy(ATTR-CM).

　　Goal:

　　reduce cardiovascular death;

　　reduce cardiovascular-related hospitalization;

　　slow disease progression.

　　Not intended for:

　　all amyloidosis types,e.g.AL amyloidosis;

　　all heart failure patients;

　　direct clearance of deposited amyloid.

　　2.Why It Works

　　In ATTR-CM,unstable TTR dissociates and misfolds,depositing in the myocardium and stiffening the heart.

　　Acoramidis is a highly selective small-molecule TTR stabilizer:

　　mimics protective TTR conformation;

　　stabilizes the TTR tetramer;

　　reduces dissociation and toxic amyloid generation;

　　preserves normal TTR transport function.

　　It works upstream,not by directly dissolving deposits.

　　3.Clinical Evidence

　　Based on the phase 3 ATTRibute-CM trial:632 symptomatic ATTR-CM adults,30 months.

　　Key results:

　　composite endpoint favored acoramidis over placebo;

　　~81%survival at 30 months vs~74%with placebo;

　　mean annual CV hospitalization about 0.3 vs 0.6;

　　functional and quality-of-life measures improved.

　　Caveats:

　　benefit is not cure;

　　outcomes vary by genotype and disease stage;

　　requires echo,biomarkers,and genetic testing context.

　　4.Use and Safety

　　oral,usually twice daily,swallow whole;

　　dose per local labeling and prescriber;

　　monitor cardiac function,renal function,electrolytes,NT-proBNP;

　　common reactions:mild GI symptoms—diarrhea,epigastric pain;

　　check CYP interactions;

　　do not self-stop,up-dose,or combine with other ATTR drugs informally.